Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22928829 | 0.89 | HPGD (0.54) | HSD11B1CYP2C9CTSKBTKEPHX1 | |
| SCHEMBL29983871 | 0.83 | BTK (0.58) | HSD11B1CYP2C9CTSKBTKEPHX1 | |
| SCHEMBL21841521 | 0.83 | HSD11B1 (0.45) | HSD11B1CYP2C9CTSKBTKEPHX1 | |
| SCHEMBL15731609 | 0.81 | HSD11B1 (0.58) | HSD11B1CYP2C9CTSKBTKEPHX1 | |
| SCHEMBL26478108 | 0.81 | BTK (0.51) | HSD11B1CYP2C9CTSKBTKEPHX1 | |
| SCHEMBL26478105 | 0.79 | HPGD (0.60) | EPHX1HPGDRECQL | |
| SCHEMBL26478102 | 0.79 | EPHX1 (0.58) | EPHX1HPGDCA1CA2RECQL | |
| SCHEMBL9225867 | 0.79 | HSD11B1 (0.55) | HSD11B1CYP2C9CTSKBTKEPHX1 | |
| SCHEMBL13240716 | 0.78 | BTK (0.63) | HSD11B1CYP2C9CTSKBTKEPHX1 | |
| SCHEMBL26255224 | 0.78 | HSD11B1 (0.52) | HSD11B1CYP2C9CTSKBTKEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | HSD11B1 2080/4885CYP2C9 4425/4885CTSK 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.